Aspirin-induced peptic ulcer and genetic polymorphisms

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue SUPPL. 1, 2010, Pages

  Shiotani, Akiko ^a   Sakakibara, Takashi ^b   Nomura, Maki ^a   Yamanaka, Yoshiyuki ^a   Nishi, Ryuji ^a   Imamura, Hiroshi ^a   Tarumi, Ken Ichi ^a   Kamada, Tomoari ^a   Hata, Jiro ^a   Haruma, Ken ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b THE SAKAKIBARA HEART INSTITUTE OF OKAYAMA   (Japan)

Author keywords

Aspirin; Cyclooxygenase 1; Helicobacter pylori; Interleukin 1 511; Polymorphisms

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYTOCHROME P450 2C9; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYP2C9 PROTEIN, HUMAN; CYTOKINE; GLUCURONOSYLTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; PTGS1 PROTEIN, HUMAN; UDP-GLUCURONOSYLTRANSFERASE, UGT1A6; UNSPECIFIC MONOOXYGENASE;

A 842G GENE; ALLELE; C50T GENE; CONFERENCE PAPER; DRUG RESISTANCE; GASTROINTESTINAL HEMORRHAGE; GENE; HELICOBACTER INFECTION; HUMAN; PEPTIC ULCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; CHEMICALLY INDUCED; COMPLICATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HELICOBACTER PYLORI; METABOLISM; MICROBIOLOGY; PATHOGENICITY; RISK ASSESSMENT; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; CYCLOOXYGENASE 1; CYTOCHROME P-450 CYP2C9; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; GLUCURONOSYLTRANSFERASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION MEDIATORS; PEPTIC ULCER; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS;

EID: 77951523654     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06212.x     Document Type: Conference Paper

References (37)

1. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997 112 : 1000 1016.
2. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999 117 : 17 25. (Pubitemid 29297615)
3. Kelly JP, Kaufman DW, Jurgelon JM et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996 348 : 1413 1416.
4. Lanas A, Bajador E, Serrano P et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N. Engl. J. Med. 2000 343 : 834 839.
5. Capet C, Czernichow P, Dupas JL et al. [Upper gastrointestinal bleeding in patients treated by low-dose aspirin]. Gastroenterol. Clin. Biol. 2001 25 : 233 238. (Pubitemid 32521305)
6. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin: what's the risk? Aliment. Pharmacol. Ther. 2006 24 : 897 908. (Pubitemid 44326371)
7. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001 120 : 594 606. (Pubitemid 32171634)
8. Awtry EH, Loscalzo J. Aspirin. Circulation 2000 101 : 1206 1218. (Pubitemid 30146625)
9. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin. Pharmacol. Ther. 2003 73 : 122 130. (Pubitemid 36158493)
10. Fujiwara T, Ikeda M, Esumi K et al. Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity. Pharmacogenomics J. 2007 7 : 395 403. (Pubitemid 350187451)
11. Arisawa T, Tahara T, Shibata T et al. Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan. Int. J. Mol. Med. 2007 20 : 373 378.
12. Shiotani A, Sakakibara T, Yamanaka Y et al. The preventive factors for aspirin-induced peptic ulcer: Aspirin ulcer and corpus atrophy. J. Gastroenterol. 2009 44 : 717 725.
13. van Oijen MG, Laheij RJ, Koetsier M et al. Effect of a specific cyclooxygenase-gene polymorphism (A-842G/C50T) on the occurrence of peptic ulcer hemorrhage. Dig. Dis. Sci. 2006 51 : 2348 2352.
14. Lampe JW, Bigler J, Horner NK et al. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999 9 : 341 349. (Pubitemid 29376378)
15. Bigler J, Whitton J, Lampe JW et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 2001 61 : 3566 3569. (Pubitemid 32694961)
16. Pilotto A, Seripa D, Franceschi M et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 2007 133 : 465 471. (Pubitemid 47193129)
17. Martinez C, Blanco G, Ladero JM et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br. J. Pharmacol. 2004 141 : 205 208. (Pubitemid 38250889)
18. Vonkeman HE, van de Laar MA, van der Palen J et al. Allele variants of the cytochrome P450 2C9 genotype in white subjects from The Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. Clin. Ther. 2006 28 : 1670 1676.
19. van Oijen MG, Huybers S, Peters WH et al. Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid. Br. J. Clin. Pharmacol. 2005 60 : 623 628. (Pubitemid 41705381)
20. Saeki M, Saito Y, Jinno H et al. Genetic polymorphisms of UGT1A6 in a Japanese population. Drug. Metab. Pharmacokinet. 2005 20 : 85 90.
21. Takahashi H, Kashima T, Nomizo Y et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin. Pharmacol. Ther. 1998 63 : 519 528. (Pubitemid 28277273)
22. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 2001 40 : 587 603. (Pubitemid 32758581)
23. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002 359 : 14 22. (Pubitemid 34119190)
24. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin. Gastroenterol. Hepatol. 2006 4 : 130 142. (Pubitemid 43199681)
25. Vergara M, Catalan M, Gisbert JP et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment. Pharmacol. Ther. 2005 21 : 1411 1418. (Pubitemid 40874157)
26. Shiotani A, Sakakibara T, Yamanaka Y et al. Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin. J. Gastroenterol. 2009 44 : 126 131.
27. Kamada T, Hata J, Kusunoki H et al. Endoscopic characteristics and Helicobacter pylori infection in NSAID-associated gastric ulcer. J. Gastroenterol. Hepatol. 2006 21 : 98 102. (Pubitemid 43126076)
28. Sakamoto C, Sugano K, Ota S et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur. J. Clin. Pharmacol. 2006 62 : 765 772. (Pubitemid 44289508)
29. Shiotani A, Kamada T, Haruma K. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J. Gastroenterol. 2008 43 : 581 588.
30. Shiotani A, Yamaoka Y, El-Zimaity HM et al. NSAID gastric ulceration: predictive value of gastric pH, mucosal density of polymorphonuclear leukocytes, or levels of IL-8 or nitrite. Dig. Dis. Sci. 2002 47 : 38 43. (Pubitemid 34075014)
31. Garcia-Gonzalez MA, Savelkoul PH, Benito R et al. No allelic variant associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease. Int. J. Immunogenet. 2005 32 : 299 306. (Pubitemid 41392374)
32. Zambon CF, Basso D, Navaglia F et al. Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine 2005 29 : 141 152. (Pubitemid 40126232)
33. Sugimoto M, Furuta T, Shirai N et al. Different effects of polymorphisms of tumor necrosis factor-alpha and interleukin-1 beta on development of peptic ulcer and gastric cancer. J. Gastroenterol. Hepatol. 2007 22 : 51 9. (Pubitemid 44953416)
34. Lu CC, Sheu BS, Chen TW et al. Host TNF-alpha-1031 and -863 promoter single nucleotide polymorphisms determine the risk of benign ulceration after H. pylori infection. Am. J. Gastroenterol. 2005 100 : 1274 1282.
35. El-Omar EM, Carrington M, Chow WH et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000 404 : 398 402. (Pubitemid 30164342)
36. Garcia-Gonzalez MA, Lanas A et al. The polymorphic IL-1B and IL-1RN genes in the aetiopathogenesis of peptic ulcer. Clin. Exp. Immunol. 2001 125 : 368 375. (Pubitemid 34155432)
37. Furuta T, El-Omar EM, Xiao F et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002 123 : 92 105. (Pubitemid 34747529)